팝업레이어 알림

RIBOZYME AND OMICS

Rznomics has core competencies to meet a variety of unmet medical needs through
development of biopharmaceutical based on RNA platform technology
for cancer/intractable diseases.

RIBOZYME AND OMICS

Rznomics has core competencies to meet a variety of unmet medical needs through
development of biopharmaceutical based on RNA platform technology
for cancer/intractable diseases.

RIBOZYME AND OMICS

Rznomics has core competencies to meet a variety of unmet medical needs through
development of biopharmaceutical based on RNA platform technology
for cancer/intractable diseases.

About Rznomics

Our vision is to treat/conquer various human intractable diseases such as hepatocellular carcinoma, intractable cancers, degenerative diseases and genetic diseases through development of innovative RNA-based biopharmaceutical.

About Rznomics

Excellence in Technology

  • 아이콘

    Dual function in a single molecule

  • 아이콘

    Modular Engineering

  • 아이콘

    Disease-related RNA target specificity

  • 아이콘

    High Performance

  • 아이콘

    Continuous regulation of gene expression

이미지

PIPELINE

Rznomics has core competencies to meet a variety of
unmet medical needs through development of
biopharmaceutical based on RNA platform 
technology for cancer/intractable diseases.

NEWS & PRESS

Latest news about Rznomics or Stay informed about Rznomics
  • Rznomics registered a U.S. patent for its original ‘circular RNA...

    Rznomics announced on the 26th that it has registered a U.S. patent for its foundational technolo...

  • Promising Anticancer Gene Therapy Makes Headway

    Promising Anticancer Gene Therapy Makes HeadwayFDA designations underscore the potential clinical i...

  • Rznomics Gene Therapy-Based Anti-Cancer Candidate Approved by FDA ...

    Rznomics has changed the manufacturing method of its anti-cancer candidate ‘RZ-001’, which is ...